跳至主要内容
临床试验/CTRI/2011/12/002253
CTRI/2011/12/002253已完成4 期

A Prospective Multicenter Observational Study to Characterize the Patient Population with Cholestasis in Chronic Liver Disease due to Alcoholic liver disease receiving Heptral in India. - ALD PMOS SAMe

Abbott India Limited0 个研究点目标入组 250 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
已完成
入组人数
250

研究概览

简要总结

暂无简介。

研究设计

研究类型
Pms

入排标准

入选标准

  • 1)Chronic liver disease due to alcoholic liver disease as diagnosed by the physician
  • 2)Intrahepatic cholestasis as diagnosed by the physician
  • 3)Age 18 to 65 years.
  • 4)Patients being prescribed Heptral according to local label.
  • 5)Patient?s written authorization to provide data for the study.

排除标准

  • 1)Contraindications to Heptral treatment including hypersensitivity according to the local label.
  • 2)Pregnancy 1-2 trimester or lactation.
  • 3)Hepatocellular or metastatic liver carcinoma.
  • 4)Severe liver disease including but not limited to ascites, hepatic encephalopathy, hypoalbuminemia, coagulopathy.
  • 5)Other conditions that make the patients participation impossible (by investigator judgment).
  • 6)Patients receiving any hepatotoxic medications

研究者

相似试验